论文部分内容阅读
目的探讨Delta样配体4(DLL-4)表达与甲状腺乳头状癌相关性。方法选取207例甲状腺乳头状癌患者为研究对象,采用免疫组化方法分析和评价DLL-4的表达,同时分析其表达与临床病理的相关性。结果 DLL-4在甲状腺乳头状癌细胞的胞浆表达为阳性,阳性表达率为54%(112/207),DLL-4阳性组患者淋巴结转移明显增多,差异有统计学意义(P<0.01);DLL-4在甲状腺乳头状癌中的表达与肿瘤浸润、转移显著相关;肿瘤体积大小(>5 mm)、甲状腺外扩散和DLL-4阳性表达与淋巴结宏转移呈正相关(P<0.05)。结论 DLL-4过度表达与甲状腺癌的浸润和转移密切相关,抗DLL-4治疗可能成为甲状腺乳头状癌治疗有效靶点。
Objective To investigate the relationship between Delta-like ligand 4 (DLL-4) expression and thyroid papillary carcinoma. Methods 207 cases of thyroid papillary carcinoma were selected as the research object. The expression of DLL-4 was analyzed by immunohistochemistry and the correlation between the expression of DLL-4 and clinical pathology was analyzed. Results The positive expression rate of DLL-4 in the cytoplasm of papillary thyroid carcinoma was 54% (112/207), and the lymph node metastasis of DLL-4 positive group was significantly increased (P <0.01) ; The expression of DLL-4 in papillary thyroid carcinoma was significantly correlated with tumor invasion and metastasis. The positive correlation between tumor size (> 5 mm), extrathyroidal spread and DLL-4 expression and lymph node metastasis (P <0.05). Conclusion The overexpression of DLL-4 is closely related to the invasion and metastasis of thyroid carcinoma. Anti-DLL-4 treatment may be an effective target for the treatment of papillary thyroid carcinoma.